# AI-Driven Cancer Drug Discovery: A 6-Month Research Execution Plan

**Reality Check**: "Curing cancer tomorrow" is scientifically impossible. Cancer comprises 200+ distinct diseases requiring decades of research. However, AI can accelerate specific aspects of cancer research. This plan focuses on **AI-enhanced drug discovery for a specific cancer type** with measurable 6-month milestones.

## 1. Problem Framing and Goals

### Primary Objective
Develop and validate AI models for accelerating small molecule drug discovery targeting **non-small cell lung cancer (NSCLC)** with specific focus on EGFR mutations [P1][P3].

### Specific Measurable Objectives
- **Drug-Target Interaction Prediction**: Achieve ≥85% AUC on EGFR binding affinity prediction (baseline: 78% from existing methods)
- **Molecular Generation**: Generate ≥1000 novel EGFR-targeting compounds with ≥70% drug-likeness score (Lipinski's Rule of Five compliance)
- **Virtual Screening Acceleration**: Reduce screening time by 50-75% compared to traditional docking methods while maintaining ≥90% hit rate preservation
- **Multi-omics Integration**: Achieve ≥80% accuracy in predicting patient response to EGFR inhibitors using genomic + transcriptomic data [P1]

### Success Criteria
- **Primary**: At least 3 AI-generated compounds show IC50 < 100nM against EGFR in biochemical assays
- **Secondary**: Published preprint with reproducible code and datasets
- **Tertiary**: Validated pipeline ready for pharmaceutical partnership discussions

## 2. Experiments (7 Core Experiments with Ablations)

### Experiment 1: Protein-Ligand Binding Affinity Prediction
**Hypothesis**: Graph neural networks with 3D structural features achieve ≥85% AUC on EGFR binding prediction. Falsify if AUC < 82%.

**Setup**:
- **Models**: GraphDTA, DeepDTA, AttentionDTA, custom GNN with 3D coordinates
- **Dataset**: PDBbind v2023 (19,443 complexes) + ChEMBL EGFR data (8,247 compounds)
- **Splits**: 80/10/10 temporal split (pre-2020/2020-2021/2022-2023)
- **Hardware**: 4x A100 GPUs, 128GB RAM

**Ablations**:
1. **Architecture**: Compare GCN vs GAT vs Transformer-based molecular encoders
2. **Features**: Molecular descriptors only vs 3D coordinates vs combined
3. **Data scale**: 1k vs 5k vs full dataset training curves
4. **Augmentation**: SMILES enumeration vs 3D conformer generation vs none
5. **Loss functions**: MSE vs ranking loss vs contrastive learning

**Baselines**: RF-Score, AutoDock Vina, existing GraphDTA results
**Metrics**: Pearson R, Spearman ρ, AUC, RMSE
**Expected Outcome**: 0.83-0.87 AUC, 0.78-0.82 Pearson R

### Experiment 2: Molecular Generation for EGFR Targeting
**Hypothesis**: Conditional VAE generates ≥70% drug-like EGFR-targeting molecules. Falsify if <60% drug-likeness or <50% predicted EGFR affinity.

**Setup**:
- **Models**: Junction Tree VAE, GraphVAE, MoFlow, custom conditional generator
- **Training Data**: ChEMBL EGFR actives (pIC50 > 6.5, n=3,247) + ZINC drug-like subset (2M compounds)
- **Conditioning**: EGFR pocket fingerprints, pharmacophore constraints
- **Generation Target**: 10,000 novel compounds per model

**Ablations**:
1. **Architecture**: VAE vs GAN vs Flow-based vs Diffusion models
2. **Conditioning**: Pocket fingerprints vs 3D pharmacophores vs target sequence
3. **Training regime**: Standard vs adversarial vs reinforcement learning
4. **Molecular representation**: SMILES vs graphs vs 3D conformers
5. **Diversity control**: Temperature scaling vs nucleus sampling vs beam search

**Evaluation**:
- **Drug-likeness**: Lipinski's Rule, QED score, SA score
- **Novelty**: Tanimoto similarity < 0.4 to training set
- **Target relevance**: Predicted EGFR binding (from Exp 1 model)
- **Synthesizability**: SAScore < 3.5, SYBA score

**Expected Outcome**: 65-75% drug-like, 40-60% novel, 30-50% EGFR-relevant

### Experiment 3: Virtual Screening Pipeline Optimization
**Hypothesis**: AI-guided virtual screening achieves ≥90% hit rate with 50× speedup vs traditional docking. Falsify if hit rate <85% or speedup <20×.

**Setup**:
- **Screening Library**: ZINC20 (1.4B compounds), ChEMBL (2.1M compounds)
- **Target**: EGFR kinase domain (PDB: 1M17, 4HJO, 5GTY)
- **Pipeline**: AI pre-filtering → molecular docking → binding affinity prediction
- **Validation**: Known EGFR inhibitors (erlotinib, gefitinib, osimertinib analogs)

**Ablations**:
1. **Pre-filtering**: Random vs pharmacophore vs AI similarity vs combined
2. **Docking software**: AutoDock Vina vs Glide vs rDock vs LeDock
3. **Scoring**: Docking score only vs ML rescoring vs consensus
4. **Filtering thresholds**: Top 0.1% vs 1% vs 5% vs 10%
5. **Ensemble methods**: Single model vs voting vs stacking

**Metrics**: 
- **Hit rate**: % of known actives recovered in top-k predictions
- **Enrichment factor**: (Hits in top-k) / (Random expectation)
- **Computational time**: CPU-hours per million compounds screened
- **Early enrichment**: AUC in top 1% of ranked compounds

**Expected Outcome**: 88-93% hit rate, 25-60× speedup, EF1% > 15

### Experiment 4: Multi-omics Patient Response Prediction
**Hypothesis**: Multi-modal deep learning predicts EGFR inhibitor response with ≥80% AUC. Falsify if AUC < 75%.

**Setup**:
- **Data**: TCGA-LUAD (n=566), GDSC cell lines (n=1,001), clinical trial data
- **Modalities**: RNA-seq (20k genes), mutations (VCF), copy number, drug sensitivity
- **Models**: Multi-modal transformers, cross-attention networks, late fusion
- **Target**: Response to erlotinib, gefitinib, afatinib (IC50 values)

**Ablations**:
1. **Fusion strategy**: Early vs intermediate vs late fusion
2. **Modality importance**: Genomics only vs transcriptomics only vs combined
3. **Architecture**: CNN vs Transformer vs Graph networks for each modality
4. **Data preprocessing**: Raw counts vs normalized vs batch-corrected
5. **Sample size**: 100 vs 300 vs 500 vs full dataset

**Validation**: 
- **Cross-validation**: 5-fold stratified by cancer subtype
- **External validation**: Independent clinical cohort (if available)
- **Interpretability**: SHAP values for top predictive features

**Expected Outcome**: 0.76-0.82 AUC, identification of 50-100 predictive biomarkers

### Experiment 5: Structure-Based Drug Design with AI
**Hypothesis**: AI-guided structure-based design generates compounds with ≥10× improved binding affinity. Falsify if improvement <5×.

**Setup**:
- **Target Structure**: EGFR kinase domain with known inhibitor binding modes
- **Starting Points**: FDA-approved EGFR inhibitors (erlotinib, gefitinib)
- **AI Methods**: Reinforcement learning, genetic algorithms, gradient-based optimization
- **Objective**: Minimize predicted binding free energy while maintaining drug-likeness

**Ablations**:
1. **Optimization method**: RL vs GA vs gradient descent vs Bayesian optimization
2. **Molecular representation**: SMILES vs 3D coordinates vs pharmacophores
3. **Scoring function**: Docking score vs ML-predicted affinity vs FEP calculations
4. **Constraints**: Drug-likeness penalties vs synthetic accessibility vs toxicity
5. **Starting diversity**: Single scaffold vs multiple scaffolds vs de novo

**Validation**:
- **Computational**: Molecular dynamics simulations (100ns per compound)
- **Experimental**: Biochemical binding assays for top 20 compounds
- **Selectivity**: Cross-reactivity against kinome panel (140 kinases)

**Expected Outcome**: 5-15× binding improvement, 80-90% drug-likeness retention

### Experiment 6: Federated Learning for Multi-institutional Data
**Hypothesis**: Federated learning maintains ≥95% of centralized model performance while preserving privacy. Falsify if performance drop >8%.

**Setup**:
- **Participants**: 3-5 simulated institutions with TCGA data splits
- **Models**: Drug response prediction models from Experiment 4
- **Privacy**: Differential privacy (ε=1.0), secure aggregation
- **Communication**: FedAvg, FedProx, personalized federated learning

**Ablations**:
1. **Aggregation method**: FedAvg vs FedProx vs FedNova vs SCAFFOLD
2. **Privacy level**: No privacy vs ε=10 vs ε=1 vs ε=0.1
3. **Data heterogeneity**: IID vs non-IID patient distributions
4. **Communication frequency**: Every round vs every 5 rounds vs adaptive
5. **Local training**: 1 epoch vs 5 epochs vs until convergence

**Metrics**: Model accuracy, privacy budget consumption, communication overhead
**Expected Outcome**: 92-97% performance retention, <2× communication cost

### Experiment 7: AI-Guided Combination Therapy Prediction
**Hypothesis**: Graph neural networks predict synergistic drug combinations with ≥75% AUC. Falsify if AUC < 70%.

**Setup**:
- **Data**: DrugComb database (448k combinations), NCI-ALMANAC (5.2M combinations)
- **Focus**: EGFR inhibitor combinations with chemotherapy/immunotherapy
- **Models**: Drug-drug interaction networks, multi-task learning, attention mechanisms
- **Validation**: Known synergistic combinations (erlotinib+bevacizumab, etc.)

**Ablations**:
1. **Network architecture**: GCN vs GAT vs GraphSAGE for drug representations
2. **Combination encoding**: Concatenation vs element-wise ops vs cross-attention
3. **Multi-task learning**: Synergy only vs synergy+toxicity+efficacy
4. **Data augmentation**: Chemical similarity vs biological pathway overlap
5. **Imbalanced learning**: Standard loss vs focal loss vs cost-sensitive learning

**Expected Outcome**: 0.72-0.78 AUC, discovery of 10-20 novel promising combinations

## 3. Timeline (26 Weeks = 13 Bi-weekly Sprints)

### Weeks 1-2: Infrastructure & Data Preparation
**Deliverables**:
- GPU cluster setup and environment configuration
- Data collection: PDBbind, ChEMBL, TCGA, DrugComb downloads
- Preprocessing pipelines for all datasets
- Baseline model implementations (GraphDTA, AutoDock Vina)
**Milestone**: All datasets processed and baseline results reproduced

### Weeks 3-4: Experiment 1 - Binding Affinity Prediction
**Deliverables**:
- 5 ablation studies completed
- Model comparison table with statistical significance tests
- Best model identified and validated on held-out test set
**Milestone**: Achieve ≥82% AUC or pivot to alternative architectures

### Weeks 5-6: Experiment 2 - Molecular Generation (Phase 1)
**Deliverables**:
- 3 generative models trained (VAE, GAN, Flow)
- Initial compound generation and drug-likeness evaluation
- Diversity and novelty analysis completed
**Milestone**: Generate 1000+ compounds with ≥60% drug-likeness

### Weeks 7-8: Experiment 3 - Virtual Screening Pipeline
**Deliverables**:
- Complete virtual screening pipeline implemented
- Benchmark against known EGFR inhibitors
- Speed and accuracy optimization completed
**Milestone**: Achieve ≥85% hit rate with ≥20× speedup

### Weeks 9-10: Experiment 2 - Molecular Generation (Phase 2)
**Deliverables**:
- Conditional generation with EGFR targeting
- Advanced ablation studies (diffusion models, RL fine-tuning)
- Top 100 compounds selected for further evaluation
**Milestone**: ≥70% drug-likeness and ≥50% predicted EGFR activity

### Weeks 11-12: Experiment 4 - Multi-omics Integration
**Deliverables**:
- Multi-modal models trained and validated
- Feature importance analysis and biomarker identification
- Cross-validation and external validation results
**Milestone**: ≥75% AUC in patient response prediction

### Weeks 13-14: Experiment 5 - Structure-Based Design
**Deliverables**:
- AI-optimized compound designs completed
- Molecular dynamics validation for top candidates
- Synthetic accessibility assessment
**Milestone**: ≥5× binding affinity improvement demonstrated

### Weeks 15-16: Experiment 6 - Federated Learning
**Deliverables**:
- Federated learning framework implemented
- Privacy-preserving model training completed
- Performance comparison with centralized approach
**Milestone**: ≥92% performance retention with privacy guarantees

### Weeks 17-18: Experiment 7 - Combination Therapy
**Deliverables**:
- Drug combination prediction models trained
- Novel combination hypotheses generated
- Literature validation of predictions
**Milestone**: ≥70% AUC in combination synergy prediction

### Weeks 19-20: Experimental Validation Preparation
**Deliverables**:
- Top 20 compounds selected for biochemical assays
- Assay protocols finalized with CRO partners
- Compound synthesis or procurement initiated
**Milestone**: Experimental validation pipeline established

### Weeks 21-22: Integration & Analysis
**Deliverables**:
- All experimental results integrated and analyzed
- Statistical significance testing across all experiments
- Failure analysis and lessons learned documentation
**Milestone**: Comprehensive results analysis completed

### Weeks 23-24: Manuscript Preparation
**Deliverables**:
- First draft of research manuscript
- Supplementary materials and code repositories
- Reproducibility documentation and tutorials
**Milestone**: Manuscript ready for internal review

### Weeks 25-26: Validation & Dissemination
**Deliverables**:
- Biochemical assay results incorporated
- Final manuscript and preprint submission
- Code release and documentation
- Conference presentation preparation
**Milestone**: Research published and code publicly available

## 4. Resources

### Computational Requirements
- **Primary Cluster**: 8x NVIDIA A100 (80GB) GPUs
- **Secondary**: 16x V100 (32GB) for parallel experiments
- **CPU**: 128 cores, 1TB RAM for data preprocessing
- **Storage**: 50TB NVMe SSD for datasets and model checkpoints
- **Estimated Cost**: $150,000-200,000 for 6 months

### Datasets and Versions
- **PDBbind v2023**: Protein-ligand binding data (19,443 complexes)
- **ChEMBL v33**: Bioactivity database (2.1M compounds, 19M activities)
- **ZINC20**: Chemical space for virtual screening (1.4B compounds)
- **TCGA-LUAD**: Lung adenocarcinoma multi-omics (566 patients)
- **GDSC v2**: Cancer cell line drug sensitivity (1,001 cell lines)
- **DrugComb v2.0**: Drug combination database (448k combinations)

### Software and Libraries
- **Deep Learning**: PyTorch 2.1, PyTorch Geometric 2.4, DGL 1.1
- **Cheminformatics**: RDKit 2023.09, OpenEye Toolkits, Schrödinger Suite
- **Molecular Modeling**: OpenMM 8.0, GROMACS 2023, AutoDock Vina 1.2
- **Data Science**: pandas 2.1, scikit-learn 1.3, NumPy 1.25
- **Visualization**: matplotlib 3.7, seaborn 0.12, PyMOL 2.5
- **Reproducibility**: MLflow 2.7, Weights & Biases, Docker containers

### Personnel Requirements
- **Principal Investigator**: 1.0 FTE (project oversight, manuscript writing)
- **Senior ML Engineer**: 1.0 FTE (model development, infrastructure)
- **Computational Biologist**: 1.0 FTE (data analysis, biological interpretation)
- **Research Associate**: 0.5 FTE (experimental validation coordination)
- **Graduate Students**: 2.0 FTE (specific experiment execution)

## 5. Risks and Mitigations

| Risk | Probability | Impact | Mitigation Strategy |
|------|-------------|--------|-------------------|
| **Data Quality Issues** | High (70%) | Medium | Implement robust data validation pipelines; use multiple data sources; manual curation of critical subsets |
| **Model Overfitting** | Medium (50%) | High | Rigorous cross-validation; external test sets; early stopping; regularization techniques |
| **Computational Resource Shortage** | Medium (40%) | High | Cloud backup resources (AWS/GCP); staged experiment execution; resource monitoring |
| **Experimental Validation Failures** | High (60%) | Medium | Select diverse compound sets; multiple assay formats; CRO backup options |
| **Reproducibility Issues** | Medium (45%) | Medium | Version control all code; containerized environments; detailed documentation |
| **Negative Results** | Medium (35%) | Low | Frame as important negative findings; focus on methodology contributions; pivot strategies |
| **Timeline Delays** | High (65%) | Medium | 20% buffer time built in; parallel experiment execution; milestone-based pivoting |
| **Key Personnel Departure** | Low (15%) | High | Cross-training; detailed documentation; backup expertise identification |

## 6. Integrated Recipe and Scaling Study

### Integration Strategy
The seven experiments form an integrated pipeline:

1. **Foundation** (Exp 1): Binding affinity prediction provides the scoring function for all downstream tasks
2. **Generation** (Exp 2): Uses Exp 1 models to evaluate generated compounds
3. **Screening** (Exp 3): Combines Exp 1 and 2 for large-scale virtual screening
4. **Personalization** (Exp 4): Adds patient-specific factors to compound selection
5. **Optimization** (Exp 5): Refines promising compounds from Exp 2-3
6. **Privacy** (Exp 6): Enables multi-institutional deployment of Exp 4
7. **Combinations** (Exp 7): Extends single-agent predictions to combination therapy

### Pareto Analysis
**Expected Trade-offs**:
- **Accuracy vs Speed**: Higher accuracy models (transformers) vs faster inference (linear models)
- **Novelty vs Drug-likeness**: More novel compounds vs higher probability of success
- **Privacy vs Performance**: Federated learning vs centralized training
- **Generalization vs Specialization**: Pan-cancer models vs EGFR-specific models

### Sensitivity Studies
**Critical Parameters**:
1. **Training Data Size**: Performance saturation curves for each model type
2. **Model Complexity**: Parameter count vs generalization performance
3. **Feature Engineering**: Impact of different molecular representations
4. **Validation Strategy**: Effect of different train/test splits on conclusions

### Success Metrics Integration
**Primary Success**: At least 3 AI-generated compounds with IC50 < 100nM against EGFR
**Secondary Success**: Validated computational pipeline with >80% accuracy across all tasks
**Tertiary Success**: Published methodology enabling broader cancer research applications

This plan represents a realistic 6-month contribution to AI-driven cancer research, focusing on measurable advances in drug discovery rather than impossible promises of immediate cures [P1][P3][P7].

## Citations

- [P1] Towards AI-Based Precision Oncology: A Machine Learning Framework for Personalized Counterfactual Treatment Suggestions based on Multi-Omics Data — http://arxiv.org/abs/2402.12190v2
- [P2] Deep Learning in Computational Biology: Advancements, Challenges, and Future Outlook — http://arxiv.org/abs/2310.03086v1
- [P3] Structure-based drug discovery with deep learning — http://arxiv.org/abs/2212.13295v1
- [P4] Social and environmental impact of recent developments in machine learning on biology and chemistry research — http://arxiv.org/abs/2210.00356v1
- [P5] Opportunities in deep learning methods development for computational biology — http://arxiv.org/abs/2406.08686v1
- [P6] Computational model discovery with reinforcement learning — http://arxiv.org/abs/2001.00008v1
- [P7] Building Flexible, Scalable, and Machine Learning-ready Multimodal Oncology Datasets — http://arxiv.org/abs/2310.01438v2
- [P8] Circuit design in biology and machine learning. I. Random networks and dimensional reduction — http://arxiv.org/abs/2408.09604v2